Summer Sale
50% off Premium Yearly
NASDAQ:GMAB
Genmab ADR (GMAB)
Financials 
Technical Analysis 
Jun 21, 2026, 12:00 amThis summary was created by AI, based on 3 opinions in the last 12 months.
Genmab ADR (GMAB-Q) is a biotech company based in the Netherlands focused on creating human antibody treatments for cancer. Recent earnings reports show a significant 19% revenue increase, driven largely by a remarkable 54% boost in sales from proprietary cancer treatments. Despite the fluctuation in stock performance, experts have varying views; some recommend covering positions due to a recent downturn, highlighting a 17% total loss from prior investments, while others urge to maintain the stock as a top pick based on solid fundamentals. The company enjoys robust cash reserves and is actively reducing its debt, largely due to a lucrative royalty agreement with Johnson & Johnson. Analysts forecast strong EPS growth and suggest a potential upside in the stock's price, continuing to endorse a protective stop-loss strategy at $24, targeting prices around $37.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentFollowing recently released earnings, we reiterate GMAB as a TOP PICK. The Danish based pharmaceutical company reported a 19% increase in revenues, thanks to a 54% increase in the sales of proprietary antibody treatments for cancer. Cash reserves grew while shares were aggressively bought back. It trades at 18x earnings, 3x book and supports a 17% ROE. We continue to recommend a stop at $24, looking to achieve $37 — upside potential of 32%. Yield 0%
(Analysts’ price target is $36.75)Premium contentGMAB is a biotech company based in the Netherlands producing human antibody treatments for cancer. It collects a royalty agreement with J&J that pays $14.3 billion, of which over half originates from the US and the balance from Europe. This is allowing for cash reserves to grow aggressively, while debt is retired. Annual EPS growth exceeds 28% over the past five years and analysts see growth over 20% over the next five. It trades at 16x earnings, 3.2x book and supports a 28% ROE. We recommend setting a stop-loss at $24, looking to achieve $37 -- upside potential of 23%. Yield 0%
(Analysts’ price target is $37.42)- «
- ‹
- 1
- ›
- »
Genmab ADR (GMAB) Frequently Asked Questions
What is Genmab ADR stock symbol?
Genmab ADR is a American stock, trading under the symbol GMAB (previously GMAB-Q on Stockchase) on the NASDAQ (GMAB). It is usually referred to as NASDAQ:GMAB or GMAB
Is Genmab ADR a buy or a sell?
In the last year, 3 stock analysts issued a Buy, Sell, or Hold rating on GMAB (previously GMAB-Q on Stockchase). 3 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for Genmab ADR.
Is Genmab ADR a good investment or a top pick?
Genmab ADR was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2026-02-12. Read the latest stock experts ratings for Genmab ADR.
Why is Genmab ADR stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Genmab ADR.
Is Genmab ADR worth watching?
Genmab ADR is covered by Stockchase experts and is worth watching.
What is Genmab ADR stock price?
On 2026-06-22, Genmab ADR (GMAB) stock closed at a price of $25.61.
'%20fill='%23FFB800'%3e%3cg%20id='filled-.-button'%20transform='translate(120.000000,%20413.999972)'%3e%3cpath%20d='M101.499729,2.82302245e-05%20C102.285413,-0.00432461793%20103.254164,0.496634241%20103.645655,1.25173399%20L103.712109,1.39623206%20L105.747863,6.45331817%20L111.028779,6.80428588%20C111.60867,6.84282525%20112.147242,7.1236355%20112.517275,7.58038413%20C113.223405,8.45199453%20113.142035,9.72214747%20112.357105,10.4940033%20L112.234099,10.6059323%20L108.072656,14.10894%20L109.356339,19.592529%20C109.472157,20.0872738%20109.394126,20.6085551%20109.13883,21.0455786%20C108.624329,21.9263208%20107.536956,22.2447485%20106.649713,21.8010736%20L106.511398,21.7246573%20L101.5,18.7715858%20L96.4886024,21.7246573%20C95.5790916,22.2767096%2094.4027498,21.9726757%2093.8611695,21.0455786%20C93.6058745,20.6085551%2093.5278433,20.0872738%2093.6436608,19.592529%20L94.9273443,14.10894%20L90.7659013,10.6059323%20C89.8680707,9.85015912%2089.7412886,8.49557505%2090.4827254,7.58038413%20C90.8527577,7.1236355%2091.39133,6.84282525%2091.9712215,6.80428588%20L97.2521374,6.45331817%20L99.2878908,1.39623206%20C99.6240254,0.561228427%20100.665516,-0.00460395016%20101.499729,2.82302245e-05%20Z'%20id='top-picks-.-icon-copy-7'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
Our PAST TOP PICK with GMAB has triggered its stop at $24. To remain disciplined, we recommend covering the position at this time. Combined with our previous guidance, this will result in a net investment loss of 17%.